APLT
NASDAQApplied Therapeutics Inc.
Price$0.11-1.19 (-91.70%)
2025-10-282026-02-02
News · 26 weeks380%
2025-10-262026-04-19
Mix2490d
- SEC Filings11(46%)
- Insider7(29%)
- Other5(21%)
- M&A1(4%)
Latest news
25 items- SECSEC Form 15-12G filed by Applied Therapeutics Inc.15-12G - Applied Therapeutics, Inc. (0001697532) (Filer)
- SECSEC Form EFFECT filed by Applied Therapeutics Inc.EFFECT - Applied Therapeutics, Inc. (0001697532) (Filer)
- SECSEC Form EFFECT filed by Applied Therapeutics Inc.EFFECT - Applied Therapeutics, Inc. (0001697532) (Filer)
- INSIDERDirector Kanter Stacy J. returned 22,500 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Applied Therapeutics, Inc. (0001697532) (Issuer)
- INSIDERChief Commercial Officer Hooks Corwin Dale was granted 312,500 shares and returned 862,500 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Applied Therapeutics, Inc. (0001697532) (Issuer)
- INSIDEROfficer Chinoporos Constantine was granted 437,500 shares and returned 1,000,000 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Applied Therapeutics, Inc. (0001697532) (Issuer)
- INSIDERDirector Skyler Jay S returned 22,500 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Applied Therapeutics, Inc. (0001697532) (Issuer)
- INSIDERChief Financial Officer Funtleyder Leslie D. was granted 1,187,500 shares and returned 2,375,000 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Applied Therapeutics, Inc. (0001697532) (Issuer)
- INSIDERChief Medical Officer Bailey Evan Prescott returned 1,235,915 shares to the company and was granted 437,500 shares, closing all direct ownership in the company (SEC Form 4)4 - Applied Therapeutics, Inc. (0001697532) (Issuer)
- INSIDERDirector Lerner Teena returned 22,500 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Applied Therapeutics, Inc. (0001697532) (Issuer)
- SECSEC Form POS AM filed by Applied Therapeutics Inc.POS AM - Applied Therapeutics, Inc. (0001697532) (Filer)
- SECSEC Form POS AM filed by Applied Therapeutics Inc.POS AM - Applied Therapeutics, Inc. (0001697532) (Filer)
- SECSEC Form S-8 POS filed by Applied Therapeutics Inc.S-8 POS - Applied Therapeutics, Inc. (0001697532) (Filer)
- SECSEC Form S-8 POS filed by Applied Therapeutics Inc.S-8 POS - Applied Therapeutics, Inc. (0001697532) (Filer)
- SECSEC Form S-8 POS filed by Applied Therapeutics Inc.S-8 POS - Applied Therapeutics, Inc. (0001697532) (Filer)
- SECSEC Form S-8 POS filed by Applied Therapeutics Inc.S-8 POS - Applied Therapeutics, Inc. (0001697532) (Filer)
- SECSEC Form 25-NSE filed by Applied Therapeutics Inc.25-NSE - Applied Therapeutics, Inc. (0001697532) (Subject)
- SECApplied Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Completion of Acquisition or Disposition of Assets, Material Modification to Rights of Security Holders, Changes in Control of Registrant8-K - Applied Therapeutics, Inc. (0001697532) (Filer)
- SECAmendment: SEC Form SC 14D9/A filed by Applied Therapeutics Inc.SC 14D9/A - Applied Therapeutics, Inc. (0001697532) (Subject)
- PRCycle Pharmaceuticals Completes Acquisition of Applied TherapeuticsCycle Group Holdings Limited ("Cycle") is delighted to announce it has completed the acquisition of NASDAQ-listed Applied Therapeutics, Inc. (NASDAQ:APLT, "Applied")), a clinical-stage biopharmaceutical company. Applied's lead drug candidate, govorestat, is a novel central nervous system (CNS) penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including Classic Galactosemia, Charcot-Marie-Tooth Sorbitol Dehydrogenase Deficiency (CMT-SORD) and phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG), for which there are currently no FDA approved treatment options available. "Cycle was founded with a commitment to support patients livi
- SECAmendment: SEC Form SC 14D9/A filed by Applied Therapeutics Inc.SC 14D9/A - Applied Therapeutics, Inc. (0001697532) (Subject)
- SECAmendment: SEC Form SC 14D9/A filed by Applied Therapeutics Inc.SC 14D9/A - Applied Therapeutics, Inc. (0001697532) (Subject)
- PRApplied Therapeutics Shares Letter to Stockholders Recommending Tender of Shares Following Offer Expiration ExtensionNEW YORK, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT) (the "Company" or "Applied"), a clinical-stage biopharmaceutical company dedicated to creating transformative treatments for rare diseases, today released the following letter to stockholders regarding the pending tender offer by AT2B, Inc. ("Purchaser"), an indirect wholly owned subsidiary of Cycle Group Holdings Limited ("Cycle"). January 29, 2026 Dear Applied Therapeutics Stockholders, As announced on December 11, 2025, we entered into a definitive agreement (the "Merger Agreement") with Cycle, a United Kingdom-based company focused on rare genetic conditions in metabolic, immunology, urology and onc
- SECAmendment: SEC Form SC 14D9/A filed by Applied Therapeutics Inc.SC 14D9/A - Applied Therapeutics, Inc. (0001697532) (Subject)
- INSIDERChief Financial Officer Funtleyder Leslie D. was granted 150,000 shares, increasing direct ownership by 13% to 1,340,459 units (SEC Form 4)4 - Applied Therapeutics, Inc. (0001697532) (Issuer)